Jessica F. Jordao1,2, Carlos A. Ayala-Grosso3,4, Yuexi Huang1, JoAnne McLaurin2, Isabelle Aubert, 2,4, Kullervo Hynynen1,5
1Imaging Research, Sunnybrook Health Sciences Centre, Toronto, ON, Canada; 2Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON, Canada; 3Unidad de Biologa Molecular, Universidad Central de Venezuela, Los Chaguaramos, Venezuela; 4Brain Sciences Research, Sunnybrook Health Sciences Centre, Toronto, ON, Canada; 5Medical Biophysics, University of Toronto, Toronto, ON, Canada
The use of antibodies to target toxic amyloid-beta peptides (Aβ) in the brain of Alzheimers patients has shown promise in clinical trials but still faces some difficulties. The blood-brain barrier remains a major obstacle; preventing intravenously delivered antibodies from reaching the brain. In this study, we use transcranial MRI-guided focused ultrasound to efficiently deliver antibodies to the brain of a mouse model of Alzheimers disease and evaluate the efficacy of this treatment. We found that delivery of the antibody is localized to targeted regions and yields a rapid and significant reduction of Aβ plaque load from a single treatment.